Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Open-label, Multiple Dose-escalation and Expansion Study of ARX788, as Monotherapy in Advanced Solid Tumors With HER2 Expression

NCT03255070 is registered in ClinicalTrials.gov with Ambrx, Inc. as lead sponsor.

NCT NCT03255070
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03255070 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Open-label, Multiple Dose-escalation and Expansion Study of ARX788, as Monotherapy in Advanced Solid Tumors With HER2 Expression
Lead sponsor
Ambrx, Inc.
Phase
Phase 1
Overall status
Completed
Start date
March 20, 2018
Completion date
October 18, 2023
Enrollment
106 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms, gastric neoplasm, solid tumors